Sees FY25 revenue $3B-$3.1B, consensus $2.92B. Sees FY25 adjusted EBITDA $650M-$675M.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- AMRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Amneal Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
- Robust Growth and Strategic Positioning Drive Buy Rating for Amneal Pharmaceuticals
- Amneal launches Mesalamine; receives U.S. FDA Lenalidomide approval
- Amneal gets FDA approval for memantine/donepezil extended-release capsules
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue